Last reviewed · How we verify
Placebo dispersible tablet
A placebo dispersible tablet contains no active pharmaceutical ingredient and produces therapeutic effects through the placebo effect.
A placebo dispersible tablet contains no active pharmaceutical ingredient and produces therapeutic effects through the placebo effect. Used for Clinical trial control arm (non-therapeutic use).
At a glance
| Generic name | Placebo dispersible tablet |
|---|---|
| Also known as | Placebo |
| Sponsor | University of Oxford |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo formulations are inert substances designed to mimic active drugs in appearance and administration route. In clinical trials, placebos serve as control comparators to isolate the true pharmacological effects of investigational drugs from psychological and contextual factors. The dispersible tablet formulation allows for flexible dosing and administration.
Approved indications
- Clinical trial control arm (non-therapeutic use)
Common side effects
- Placebo response (symptom improvement without active ingredient)
Key clinical trials
- A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine (PHASE3)
- Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease (PHASE3)
- A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC) (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis (PHASE3)
- Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE) (PHASE2)
- The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo dispersible tablet CI brief — competitive landscape report
- Placebo dispersible tablet updates RSS · CI watch RSS
- University of Oxford portfolio CI